Related to Ticking Time Bomb: Resetting the Flu’s Clock

• Swiss Institute Spins Out Human mAb Therapeutics Firm
  
• Kary Mullis, Ph.D., Joins Loxbridge in Setting Up Firm to Tackle Drug-Resistant Pathogens
  
• United Therapeutics Wins NIAID Contract Worth $45M to Develop Broad-Spectrum Antiviral Drug
  
• Arsanis Wins €1.2M for Research on Antibody Against Hospital-Acquired Infections
  
• CureVac, Sanofi Pasteur, and In-Cell-Art Collaborate on €33.1M DARPA-Supported Vaccine Program
  
• Lonza to Deimmunize ImmuneMed’s Virus Suppressing Factor
  
• TaiGen Acquires Global Rights to Warner Chilcott's Late-Stage Antibiotic
  
• Translational Medicine Center for Infectious Diseases Set Up in Shanghai
  
• TrovaGene to Buy MultiGen’s CLIA Lab to Bolster Infectious Disease Testing
  
• BMS to Buy Anti-Infectives Firm Inhibitex for $2.5B in Cash
  
• Scientists Identify New Target for Apicomplexan Pathogens
  
• Life Technologies, DaAn Establish Chinese Diagnostics Joint Venture
  
• Scil, Almac Separately Report New Contract Manufacturing Deals
  
• Pherecydes Receives Grant to Develop Bacteriophage Therapies for Skin Infections
  
• Lab21 Licenses Cooperative Diagnostics’ RT-PCR IP for MDx Assay Development
  
• Interleukin Released on Viral Infection Directly Stimulates CTL Response
  
• BioConnections Licenses Hebrew University’s Rapid MDR Infection Test Kits
  
• FDA Clears MedImmune’s FluMist Quadrivalent Flu Vaccine
  
• LaserGen Wins Grant for Next-Gen Sequencing Test for Wound Infection Pathogens
  
• DoD Awards MediVector $138.5M for Broad Spectrum Flu Therapeutic